

Michael Manns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4543271/publications.pdf>

Version: 2024-02-01

388
papers

29,112
citations

10351

72
h-index

6282

158
g-index

400
all docs

400
docs citations

400
times ranked

23215
citing authors

#	ARTICLE	IF	CITATIONS
1	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. <i>Lancet, The</i> , 2001, 358, 958-965.	6.3	5,888
2	Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i> , 2010, 51, 2193-2213.	3.6	1,243
3	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
4	Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. <i>Nature Medicine</i> , 2000, 6, 578-582.	15.2	697
5	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
6	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. <i>New England Journal of Medicine</i> , 2017, 376, 2134-2146.	13.9	467
7	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 685-697.	4.6	402
8	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	1.8	401
9	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 1198-1206.	0.6	394
10	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2014, 384, 414-426.	6.3	376
11	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
12	Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17006.	18.1	354
13	Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 107-114.	0.2	353
14	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	0.6	317
15	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet, The</i> , 2014, 384, 1597-1605.	6.3	316
16	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. <i>Gastroenterology</i> , 2015, 149, 1345-1360.	0.6	306
17	Autoimmune hepatitis - Update 2015. <i>Journal of Hepatology</i> , 2015, 62, S100-S111.	1.8	290
18	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282

#	ARTICLE	IF	CITATIONS
19	Autoimmune hepatitis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18017.	18.1	280
20	The way forward in HCV treatment – finding the right path. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 991-1000.	21.5	267
21	The EASL “Lancet Liver Commission; protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	6.3	257
22	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , 2011, 54, 1947-1955.	3.6	255
23	Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 58-72.e4.	0.6	252
24	Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. <i>Hepatology</i> , 2002, 35, 126-131.	3.6	231
25	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
26	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006, 43, 250-256.	3.6	229
27	Autoimmune hepatitis: Clinical challenges. <i>Gastroenterology</i> , 2001, 120, 1502-1517.	0.6	210
28	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
29	Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis. <i>Cell Stem Cell</i> , 2016, 18, 797-808.	5.2	181
30	Novel therapies for hepatitis C – one pill fits all?. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 595-610.	21.5	174
31	Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. <i>Journal of Experimental Medicine</i> , 2008, 205, 1409-1422.	4.2	173
32	A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates With Ribavirin Treatment Failure in Organ Transplant Recipients. <i>Gastroenterology</i> , 2014, 147, 1008-1011.e7.	0.6	171
33	Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. <i>Journal of Hepatology</i> , 1999, 31, 39-42.	1.8	170
34	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640.	3.7	165
35	Treatment With Ledipasvir + Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 109.	2.0	164
36	Autoimmune hepatitis, from mechanisms to therapy. <i>Hepatology</i> , 2006, 43, S132-S144.	3.6	159

#	ARTICLE	IF	CITATIONS
37	The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2123-2131.	1.3	159
38	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
39	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , 2016, 65, 1733-1743.	6.1	145
40	Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. <i>Hepatology</i> , 2011, 53, 875-884.	3.6	143
41	Nonreversible MAIT cell dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. <i>European Journal of Immunology</i> , 2016, 46, 2204-2210.	1.6	142
42	Scent dog identification of samples from COVID-19 patients – a pilot study. <i>BMC Infectious Diseases</i> , 2020, 20, 536.	1.3	132
43	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	4.6	128
44	Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2016, 214, 1965-1974.	1.9	127
45	Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hb ig immunoglobulin after liver transplantation. <i>Hepatology</i> , 1999, 30, 244-256.	3.6	125
46	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> , 2019, 69, 684-698.	3.6	121
47	Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. <i>Journal of Hepatology</i> , 2014, 61, 1106-1114.	1.8	119
48	The impact of hepatitis E in the liver transplant setting. <i>Journal of Hepatology</i> , 2014, 61, 1418-1429.	1.8	115
49	Prediction of short- and long-term outcome in patients with autoimmune hepatitis. <i>Hepatology</i> , 2015, 62, 1524-1535.	3.6	115
50	Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. <i>Journal of Autoimmunity</i> , 2019, 103, 102289.	3.0	115
51	Hyperstimulation With Interleukin 6 Inhibits Cell Cycle Progression After Hepatectomy in Mice. <i>Hepatology</i> , 2000, 32, 514-522.	3.6	111
52	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. <i>Liver Transplantation</i> , 2016, 22, 42-52.	1.3	111
53	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 215-222.	4.6	109
54	MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 122-134.	1.8	109

#	ARTICLE	IF	CITATIONS
55	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2011, 54, 1114-1122.	1.8	105
56	The microRNA-449 family inhibits TGF- β -mediated liver cancer cell migration by targeting SOX4. <i>Journal of Hepatology</i> , 2017, 66, 1012-1021.	1.8	102
57	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. <i>Liver International</i> , 2019, 39, 1868-1875.	1.9	97
58	Cutting edge issues in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2016, 75, 6-19.	3.0	96
59	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 584-593.	1.8	95
60	Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. <i>PLoS ONE</i> , 2013, 8, e55285.	1.1	91
61	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. <i>Oncologist</i> , 2014, 19, 1156-1168.	1.9	90
62	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	1.8	90
63	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. <i>Cell Death and Disease</i> , 2020, 11, 212.	2.7	90
64	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, 561-567.	2.9	89
65	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017, 65, 414-425.	3.6	88
66	MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0139305.	1.1	88
67	Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. <i>Liver Transplantation</i> , 1996, 2, 253-262.	1.9	87
68	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	1.8	85
69	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 497-506.	4.6	84
70	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <i>Current Gastroenterology Reports</i> , 2002, 4, 23-30.	1.1	82
71	Recurrent Autoimmune Hepatitis After Liver Transplantation—When Non-self Becomes Self. <i>Hepatology</i> , 2000, 32, 868-870.	3.6	75
72	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , 2018, 9, 2275.	5.8	75

#	ARTICLE	IF	CITATIONS
73	Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4 ⁺ T cells. <i>Hepatology</i> , 2013, 58, 718-728.	3.6	74
74	HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. <i>Lancet Infectious Diseases</i> , 2014, 14, 678-679.	4.6	73
75	Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. <i>Hepatology</i> , 1999, 30, 1159-1166.	3.6	72
76	Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. <i>Liver International</i> , 2018, 38, 50-58.	1.9	72
77	Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , 2018, 38, 842-850.	1.9	72
78	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). <i>Journal of Hepatology</i> , 2021, 75, 1346-1354.	1.8	69
79	Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. <i>Cancer Cell</i> , 2016, 30, 308-323.	7.7	68
80	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	1.8	68
81	M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?. <i>Hepatology</i> , 1992, 16, 1128-1136.	3.6	67
82	Plasma bile acids are not associated with energy metabolism in humans. <i>Nutrition and Metabolism</i> , 2010, 7, 73.	1.3	67
83	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1733-1738.	2.4	66
84	Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. <i>Gastroenterology</i> , 2016, 151, 338-350.e7.	0.6	65
85	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , 2016, 65, 473-482.	1.8	64
86	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	1.8	64
87	Soluble liver antigen: Isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. <i>Hepatology</i> , 2001, 33, 591-596.	3.6	63
88	Involvement of Proteasome β -Subunit PSMA7 in Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation. <i>Molecular and Cellular Biology</i> , 2001, 21, 8357-8364.	1.1	63
89	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019, 71, 301-312.	1.8	62
90	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 533-550.	8.2	62

#	ARTICLE	IF	CITATIONS
91	Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 1997, 32, 480-486.	2.3	61
92	Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. <i>Liver International</i> , 2000, 20, 312-318.	1.9	61
93	Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis. <i>PLoS ONE</i> , 2014, 9, e85330.	1.1	61
94	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	2.4	61
95	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 475-488.	0.4	61
96	Transcriptome Profiling Identifies TIGIT as a Marker of T Cell Exhaustion in Liver Cancer. <i>Hepatology</i> , 2021, 73, 1399-1418.	3.6	61
97	Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. <i>Antiviral Therapy</i> , 2011, 16, 1021-1033.	0.6	59
98	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	1.8	59
99	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 781-793.	3.7	58
100	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2342-2349.e2.	2.4	57
101	Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. <i>Cell Reports</i> , 2016, 17, 2234-2246.	2.9	57
102	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , 2018, 217, 1656-1666.	1.9	57
103	Explanted Diseased Livers – A Possible Source of Metabolic Competent Primary Human Hepatocytes. <i>PLoS ONE</i> , 2014, 9, e101386.	1.1	55
104	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2068-2075.e2.	2.4	55
105	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2020, 73, 1496-1506.	1.8	55
106	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 321-329.	1.8	55
107	An Extended qPCR-Method Facilitating Normalisation with Multiple Reference Genes Suited for Quantitative RT-PCR Analyses of Human Hepatocyte-Like Cells. <i>PLoS ONE</i> , 2014, 9, e93031.	1.1	54
108	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 361-368.	1.0	53

#	ARTICLE	IF	CITATIONS
109	The Pre-S region determines the intracellular localization and appearance of hepatitis B virus. <i>Hepatology</i> , 1999, 30, 517-525.	3.6	52
110	Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. <i>Hepatology</i> , 2012, 56, 884-893.	3.6	52
111	Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. <i>Visceral Medicine</i> , 2019, 35, 161-170.	0.5	52
112	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 889-899.	1.8	52
113	Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , 2015, 64, 469-482.	6.1	51
114	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. <i>Journal of Hepatology</i> , 2017, 67, 480-489.	1.8	51
115	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 31-40.	1.8	50
116	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. <i>Journal of Hepatology</i> , 2018, 69, 1221-1230.	1.8	50
117	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	1.1	50
118	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 714-726.	1.9	49
119	Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. <i>Journal of Autoimmunity</i> , 2011, 37, 242-253.	3.0	48
120	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. <i>JHEP Reports</i> , 2019, 1, 437-445.	2.6	48
121	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 554-563.	1.8	47
122	Host cell mTORC1 is required for HCV RNA replication. <i>Gut</i> , 2016, 65, 2017-2028.	6.1	47
123	Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 696-706.	1.9	47
124	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	1.0	47
125	Target Proteins in Human Autoimmunity: Cytochromes P450 and Udp-Glycoronosyltransferases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 429-439.	1.8	46
126	Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1227-1234.	0.6	46

#	ARTICLE	IF	CITATIONS
127	p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury. <i>Gut</i> , 2014, 63, 1501-1512.	6.1	45
128	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	2.9	45
129	Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. <i>Liver Transplantation</i> , 2003, 9, 191-196.	1.3	44
130	Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. <i>BMC Gastroenterology</i> , 2015, 15, 60.	0.8	42
131	MicroRNA-125b-5p mimic inhibits acute liver failure. <i>Nature Communications</i> , 2016, 7, 11916.	5.8	42
132	Noninvasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017, 37, 196-204.	1.9	42
133	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
134	Therapeutic plasma exchange in acute liver failure. <i>Journal of Clinical Apheresis</i> , 2019, 34, 589-597.	0.7	42
135	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
136	Cholemic Nephropathy Causes Acute Kidney Injury and Is Accompanied by Loss of Aquaporin 2 in Collecting Ducts. <i>Hepatology</i> , 2019, 69, 2107-2119.	3.6	41
137	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. <i>Journal of Virology</i> , 2011, 85, 7613-7621.	1.5	40
138	Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. <i>Journal of Lipid Research</i> , 2013, 54, 2195-2205.	2.0	40
139	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020, 73, 696-699.	1.8	39
140	Treatment of HBV/HCV coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 919-928.	0.9	38
141	The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 366-376.e6.	0.6	38
142	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 1480-1484.	1.9	38
143	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019, 8, 41-65.	4.2	38
144	Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. <i>Journal of Hepatology</i> , 2019, 70, 722-734.	1.8	38

#	ARTICLE	IF	CITATIONS
145	Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells. <i>Cut</i> , 2020, 69, 1104-1115.	6.1	37
146	Autoimmunity in Liver Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2000, 18, 127-140.	2.9	36
147	High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1063-1069.	1.8	35
148	Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. <i>Liver International</i> , 2015, 35, 2042-2049.	1.9	35
149	MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. <i>Journal of Hepatology</i> , 2015, 62, 101-110.	1.8	35
150	BaiCD gene cluster abundance is negatively correlated with <i>Clostridium difficile</i> infection. <i>PLoS ONE</i> , 2018, 13, e0196977.	1.1	34
151	Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G164-G172.	1.6	33
152	Autoimmune hepatitis. <i>Current Gastroenterology Reports</i> , 2005, 7, 81-83.	1.1	33
153	Sofosbuvir: the final nail in the coffin for hepatitis C?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 378-379.	4.6	33
154	Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. <i>PLoS ONE</i> , 2017, 12, e0179074.	1.1	33
155	Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. <i>Liver International</i> , 2018, 38, 1602-1613.	1.9	33
156	Ex Vivo/In Vivo Gene Editing in Hepatocytes Using "All-in-One" CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template. <i>IScience</i> , 2020, 23, 100764.	1.9	33
157	Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. <i>PLoS ONE</i> , 2017, 12, e0181107.	1.1	33
158	Lipid Evaluation in HIV-1-Positive Patients Treated with Protease Inhibitors. <i>Antiviral Therapy</i> , 1999, 4, 163-170.	0.6	33
159	Current State of Interferon Therapy in the Treatment of Chronic Hepatitis B. <i>Seminars in Liver Disease</i> , 2002, 22, 007-014.	1.8	32
160	Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. <i>Liver International</i> , 2012, 32, 27-31.	1.9	32
161	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8 ⁺ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , 2015, 89, 8304-8317.	1.5	32
162	Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens. <i>Hepatology</i> , 2015, 61, 1295-1305.	3.6	32

#	ARTICLE	IF	CITATIONS
163	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017, 215, 139-149.	1.9	32
164	DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. <i>Transplantation</i> , 2020, 104, 551-561.	0.5	32
165	Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2021, 117, 102591.	3.0	32
166	Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing cholangitis. <i>Journal of Infection</i> , 2015, 70, 483-490.	1.7	31
167	Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. <i>European Radiology</i> , 2019, 29, 1882-1892.	2.3	31
168	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. <i>Hepatology</i> , 2020, 72, 753-769.	3.6	30
169	Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. <i>Transplant Infectious Disease</i> , 2001, 3, 16-23.	0.7	29
170	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. <i>Hepatology</i> , 2020, 72, 1378-1393.	3.6	29
171	Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. <i>Scientific Reports</i> , 2020, 10, 14242.	1.6	29
172	Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. <i>Digestive Diseases and Sciences</i> , 1996, 41, 27S-40S.	1.1	28
173	Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis. <i>Digestive and Liver Disease</i> , 2014, 46, 625-631.	0.4	28
174	The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1347-1355.	1.2	28
175	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. <i>Antiviral Research</i> , 2017, 147, 19-28.	1.9	28
176	Novel therapeutic targets in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2018, 95, 34-46.	3.0	28
177	Second-wave Protease Inhibitors: Choosing an Heir. <i>Clinics in Liver Disease</i> , 2011, 15, 597-609.	1.0	27
178	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , 2015, 6, 270.	2.2	27
179	Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. <i>Liver International</i> , 2019, 39, 54-59.	1.9	27
180	Future landscape of hepatitis C research – Basic, translational and clinical perspectives. <i>Journal of Hepatology</i> , 2016, 65, S143-S155.	1.8	26

#	ARTICLE	IF	CITATIONS
181	Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2113-2121.	1.2	26
182	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. <i>Journal of Hepatology</i> , 2017, 67, 237-245.	1.8	26
183	Autoimmune Polyglandular Syndrome Type 1. <i>Clinical Reviews in Allergy and Immunology</i> , 2000, 18, 167-184.	2.9	25
184	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , 2015, 35, 1845-1852.	1.9	25
185	Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts. <i>Liver Transplantation</i> , 2016, 22, 943-955.	1.3	25
186	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. <i>Frontiers in Immunology</i> , 2017, 8, 525.	2.2	25
187	Transient increase of activated regulatory T cells early after kidney transplantation. <i>Scientific Reports</i> , 2019, 9, 1021.	1.6	25
188	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , 2019, 71, 673-684.	1.8	25
189	Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors. <i>Liver International</i> , 2019, 39, 914-923.	1.9	25
190	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1609-1617.e4.	2.4	25
191	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	2.4	25
192	Adherence to combination therapy: influence on sustained virologic response and economic impact. <i>Gastroenterology Clinics of North America</i> , 2004, 33, 11-24.	1.0	24
193	SLA/LP/tRNP(Ser)Sec antigen in autoimmune hepatitis: Identification of the native protein in human hepatic cell extract. <i>Journal of Autoimmunity</i> , 2010, 34, 59-65.	3.0	24
194	The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. <i>Journal of Autoimmunity</i> , 2017, 78, 39-45.	3.0	24
195	Scent dog identification of SARS-CoV-2 infections in different body fluids. <i>BMC Infectious Diseases</i> , 2021, 21, 707.	1.3	24
196	Ras adenoviruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy. <i>Oncogene</i> , 2001, 20, 5264-5278.	2.6	23
197	Autoimmunity and viruses. <i>Clinics in Liver Disease</i> , 2002, 6, 739-753.	1.0	23
198	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	2.9	23

#	ARTICLE	IF	CITATIONS
199	A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin. <i>United European Gastroenterology Journal</i> , 2017, 5, 668-676.	1.6	23
200	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , 2018, 6, 1188-1198.	1.6	23
201	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e189.	1.3	23
202	Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. <i>Oncotarget</i> , 2018, 9, 17430-17442.	0.8	23
203	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 296-304.	3.7	23
204	Angiopoietin-2 and Biliary Diseases: Elevated Serum, but Not Bile Levels Are Associated with Cholangiocarcinoma. <i>PLoS ONE</i> , 2014, 9, e97046.	1.1	23
205	IL-18 gene therapy in tumor necrosis factor- α - and chemotherapy-mediated apoptosis of hepatocellular carcinomas. <i>Cancer Gene Therapy</i> , 2000, 7, 1315-1323.	2.2	22
206	Hepatic amino-acid metabolism in liver cirrhosis and in the long-term course after liver transplantation. <i>Transplant International</i> , 2003, 16, 1-8.	0.8	22
207	Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis. <i>Cell Death and Disease</i> , 2017, 8, 3219.	2.7	22
208	Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. <i>United European Gastroenterology Journal</i> , 2018, 6, 213-224.	1.6	22
209	Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. <i>Scientific Reports</i> , 2018, 8, 17452.	1.6	22
210	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. <i>Journal of Hepatology</i> , 2018, 69, 982-984.	1.8	22
211	The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality. <i>Liver International</i> , 2020, 40, 149-153.	1.9	22
212	Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. <i>Journal of Medical Microbiology</i> , 2018, 67, 1496-1508.	0.7	22
213	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon- α 2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 303-316.	0.6	22
214	Risk estimation for biliary tract cancer: Development and validation of a prognostic score. <i>Liver International</i> , 2017, 37, 1852-1860.	1.9	21
215	The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2022, 6, 320-333.	2.0	21
216	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21

#	ARTICLE	IF	CITATIONS
217	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , 2019, 70, 593-602.	1.8	20
218	The Lancetâ€EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. <i>Lancet, The</i> , 2018, 392, 621-622.	6.3	19
219	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00066.	1.3	19
220	Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma. <i>Journal of Biomedical Science</i> , 2020, 27, 13.	2.6	19
221	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021, 74, 72-82.	3.6	19
222	Liver transplantation for critically ill patients with secondary sclerosing cholangitis: Outcome and complications. <i>Liver Transplantation</i> , 2015, 21, 1295-1299.	1.3	18
223	Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1647-1656.	0.8	18
224	The Role of Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Biliary Atresia: 14 Years' Experience. <i>European Journal of Pediatric Surgery</i> , 2018, 28, 261-267.	0.7	18
225	Hepatitis E virus <scp>ORF</scp> 1 induces proliferative and functional Tâ€cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , 2018, 38, 266-277.	1.9	18
226	Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1107-1113.	0.6	18
227	Clinical significance of detectable and quantifiable <scp>HCV RNA</scp> at the end of treatment with ledipasvir/sofosbuvir in <scp>GT</scp>1 patients. <i>Liver International</i> , 2018, 38, 1906-1910.	1.9	18
228	Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3003-3012.	1.2	18
229	Residual low HDV viraemia is associated HDV RNA relapse after PEGâ€FNaâ€based antiviral treatment of hepatitis delta: Results from the HIDITâ€ study. <i>Liver International</i> , 2021, 41, 295-299.	1.9	18
230	Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2022, 226, 441-452.	1.9	18
231	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , 2021, 9, 353.	1.4	18
232	Recent developments in autoimmune liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S256-S271.	1.4	17
233	Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1730-1738.	1.4	17
234	Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia. <i>American Journal of Hematology</i> , 2017, 92, E641-E644.	2.0	17

#	ARTICLE	IF	CITATIONS
235	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 238-246.	1.6	17
236	Unmet needs and new models for future trials in autoimmune hepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 363-370.	3.7	17
237	Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 186-189.	2.4	17
238	Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts. <i>United European Gastroenterology Journal</i> , 2018, 6, 919-925.	1.6	17
239	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	1.9	17
240	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa040.	0.4	17
241	The <i>PNPLA3</i> rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1160-1168.	1.9	17
242	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e94512.	1.1	17
243	Liver Cirrhosis, Transplantation and Organ Shortage. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 83-4.	0.6	17
244	Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. <i>Frontiers in Medicine</i> , 2021, 8, 749588.	1.2	17
245	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 848-856.	0.2	16
246	An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 192-199.e3.	2.4	16
247	Outcomes of renal dysfunction in patients with acute liver failure. <i>United European Gastroenterology Journal</i> , 2019, 7, 388-396.	1.6	16
248	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	1.9	16
249	Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. <i>Liver International</i> , 2020, 40, 1225-1238.	1.9	16
250	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
251	Autoimmune Hepatitis. <i>Seminars in Liver Disease</i> , 2009, 29, 239-240.	1.8	15
252	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. <i>PLoS ONE</i> , 2014, 9, e108751.	1.1	15

#	ARTICLE	IF	CITATIONS
253	Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. <i>Liver International</i> , 2014, 34, 707-719.	1.9	15
254	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1806-1812.	2.4	15
255	No cure for hepatitis B and D without targeting integrated viral DNA?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 195-196.	8.2	15
256	Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. <i>Scientific Reports</i> , 2018, 8, 419.	1.6	15
257	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. <i>Hepatology Communications</i> , 2022, 6, 480-495.	2.0	15
258	Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e110857.	1.1	15
259	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. <i>Liver International</i> , 2016, 36, 954-962.	1.9	14
260	Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2931-2952.	1.4	14
261	Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. <i>Journal of Autoimmunity</i> , 2018, 91, 83-96.	3.0	14
262	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , 2019, 9, 14118.	1.6	14
263	Overcoming fragmentation of health research in Europe: lessons from COVID-19. <i>Lancet</i> , 2020, 395, 1970-1971.	6.3	14
264	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	1.0	14
265	Gray scale and contrast-enhanced ultrasound imaging of malignant liver tumors of vascular origin. <i>United European Gastroenterology Journal</i> , 2015, 3, 63-71.	1.6	13
266	Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2016, 80, 1-7.	1.6	13
267	Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 116-124.	0.6	13
268	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1033-1041.	0.6	13
269	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. <i>Liver International</i> , 2020, 40, 324-332.	1.9	13
270	Nonocclusive Mesenteric Ischemia and Interventional Local Vasodilatory Therapy: A Meta-Analysis and Systematic Review of the Literature. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 128-139.	1.3	13

#	ARTICLE	IF	CITATIONS
271	Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). <i>European Journal of Radiology</i> , 2020, 129, 109101.	1.2	13
272	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	13
273	Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. <i>United European Gastroenterology Journal</i> , 2020, 8, 567-576.	1.6	13
274	Î² gene therapy in tumor necrosis factor-Î± and chemotherapy-mediated apoptosis of hepatocellular carcinomas. <i>Cancer Gene Therapy</i> , 2000, 7, 1315-1323.	2.2	13
275	Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , 2020, 8, 716-724.	1.6	13
276	Decreased splanchnic oxygen uptake and increased systemic oxygen uptake in cirrhosis are normalized after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 1015-1022.	1.3	12
277	Therapeutic Strategies for Autoimmune Hepatitis. <i>Digestive Diseases</i> , 2011, 29, 411-415.	0.8	12
278	Shear wave elastography prior to transjugular intrahepatic portosystemic shunt may predict the decrease in hepatic vein pressure gradient. <i>Abdominal Radiology</i> , 2019, 44, 1127-1134.	1.0	12
279	Present and future therapy for hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 781-793.	2.0	11
280	Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. <i>Journal of Leukocyte Biology</i> , 2015, 98, 283-294.	1.5	11
281	Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0220666.	1.1	11
282	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2076.	2.2	11
283	Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. <i>Cancers</i> , 2019, 11, 1904.	1.7	11
284	Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2019, 26, 224-230.	1.0	11
285	High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 817768.	2.0	11
286	Cytochrome P450 enzymes and UDP-Glucuronosyltransferases as hepatocellular autoantigens. <i>Molecular Biology Reports</i> , 1996, 23, 235-242.	1.0	10
287	Morphological and molecular characterization of human gastric mucous cells in long-term primary culture. <i>Pflügers Archiv European Journal of Physiology</i> , 1998, 436, 871-881.	1.3	10
288	New kids on the block – step by step to an ideal HCV therapy. <i>Lancet</i> , The, 2015, 385, 1050-1052.	6.3	10

#	ARTICLE	IF	CITATIONS
289	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 609-618.	1.4	10
290	Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress. <i>Toxicological Sciences</i> , 2017, 159, 402-412.	1.4	10
291	Homologous recombination mediates stable Fah gene integration and phenotypic correction in tyrosinaemia mouse-model. <i>World Journal of Hepatology</i> , 2018, 10, 277-286.	0.8	10
292	Quality of Life Is Associated With Wearable-Based Physical Activity in Patients With Inflammatory Bowel Disease: A Prospective, Observational Study. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00094.	1.3	10
293	Autoimmune hepatitis induction can occur in the liver. <i>Liver International</i> , 2020, 40, 377-381.	1.9	10
294	Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosisâ€”A multicentre study. <i>EBioMedicine</i> , 2020, 62, 103083.	2.7	10
295	Therapeutic plasma exchange in acute on chronic liver failure. <i>Journal of Clinical Apheresis</i> , 2020, 35, 316-327.	0.7	10
296	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.	2.4	10
297	M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?. <i>Hepatology</i> , 1992, 16, 1128-1136.	3.6	10
298	Autoimmune hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 291-306.	1.0	9
299	Optimal treatment with boceprevir for chronic HCV infection. <i>Liver International</i> , 2013, 33, 14-22.	1.9	9
300	The BH3â€”only protein BID impairs the p38â€”mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice. <i>Hepatology</i> , 2015, 62, 816-828.	3.6	9
301	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. <i>Antiviral Research</i> , 2017, 141, 116-123.	1.9	9
302	Systemic inflammation and immune cell phenotypes are associated with neuroâ€”psychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , 2018, 38, 2317-2328.	1.9	9
303	Realâ€”world effect of ribavirin on quality of life in <sc>HCV</sc>â€”infected patients receiving interferonâ€”free treatment. <i>Liver International</i> , 2018, 38, 834-841.	1.9	9
304	Restoration of mucosal integrity and epithelial transport function by concomitant anti-TNFÎ± treatment in chronic DSS-induced colitis. <i>Journal of Molecular Medicine</i> , 2018, 96, 831-843.	1.7	9
305	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. <i>Journal of Hepatology</i> , 2019, 70, 603-614.	1.8	9
306	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , 2020, 2, 100060.	2.6	9

#	ARTICLE	IF	CITATIONS
307	Increase of α -dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. <i>Oncolmmunology</i> , 2021, 10, 1874159.	2.1	9
308	Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. <i>Cells</i> , 2021, 10, 1471.	1.8	9
309	Hepatitis C and autoimmune hepatitis. <i>Hepatology</i> , 2000, 31, 811-812.	3.6	8
310	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2015, 10, e0140525.	1.1	8
311	Scientific Panel for Health: better research for better health. <i>Lancet, The</i> , 2016, 388, 865-866.	6.3	8
312	Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. <i>Liver International</i> , 2017, 37, 1468-1475.	1.9	8
313	Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations. <i>Molecular Therapy</i> , 2017, 25, 2533-2545.	3.7	8
314	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 194-195.	1.9	8
315	Short-Term Regulation of Murine Colonic NBCe1-B (Electrogenic Na ⁺ /HCO ₃ ⁻ Cotransporter) Membrane Expression and Activity by Protein Kinase C. <i>PLoS ONE</i> , 2014, 9, e92275.	1.1	7
316	Regional differences in health care of patients with inflammatory bowel disease in Germany. <i>Health Economics Review</i> , 2015, 5, 29.	0.8	7
317	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. <i>Gut</i> , 2016, 65, 1015-1023.	6.1	7
318	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. <i>Viruses</i> , 2019, 11, 275.	1.5	7
319	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1049-1056.	0.8	7
320	Recommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 69, 1358-1359.	3.6	7
321	Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. <i>PLoS ONE</i> , 2020, 15, e0235199.	1.1	7
322	Fully automated detection of primary sclerosing cholangitis (PSC)-compatible bile duct changes based on 3D magnetic resonance cholangiopancreatography using machine learning. <i>European Radiology</i> , 2021, 31, 2482-2489.	2.3	7
323	Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3786.	1.7	7
324	Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C – Results from the German Hepatitis C-Registry (DHC-R). <i>Biomedicines</i> , 2021, 9, 1495.	1.4	7

#	ARTICLE	IF	CITATIONS
325	Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. <i>Liver International</i> , 2017, 37, 67-72.	1.9	6
326	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 26, 466-475.	1.0	6
327	Microbiota-associated Risk Factors for <i>Clostridioides difficile</i> Acquisition in Hospitalized Patients: A Prospective, Multicentric Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2625-e2634.	2.9	6
328	Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. <i>Biomedicines</i> , 2021, 9, 58.	1.4	6
329	The curing regimens of HCV: A SWOT analysis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110726.	0.6	6
330	Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. <i>Antiviral Research</i> , 2015, 124, 122-131.	1.9	5
331	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0128069.	1.1	5
332	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 285-294.e1.	2.3	5
333	Hepatitis C: individualised medicine versus one pill fits all. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 86-87.	3.7	5
334	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , 2018, 68, 851-853.	1.8	5
335	A transient early HBV DNA increase during PEG therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.	1.0	5
336	Immunoglobulin G4-associated cholangitis: Dominating immunoglobulin G4-positive clones within the B-cell receptor repertoire indicate light at the end of a long tunnel. <i>Hepatology</i> , 2013, 57, 2110-2113.	3.6	4
337	Treatment of autoimmune hepatitis. <i>Clinical Liver Disease</i> , 2014, 3, 15-17.	1.0	4
338	Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , 2021, 41, 1815-1823.	1.9	4
339	Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. <i>Drugs in Context</i> , 2016, 5, 1-9.	1.0	4
340	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 841-846.	0.2	4
341	The biliary microbiome in ischaemic-type biliary lesions can be shaped by stenting but is resilient to antibiotic treatment. <i>Liver International</i> , 2022, 42, 1070-1083.	1.9	4
342	Acute hepatitis C infection: Can immunology teach us the right way to treat?. <i>Current Hepatitis Reports</i> , 2004, 3, 148-156.	0.3	3

#	ARTICLE	IF	CITATIONS
343	Future trends in hepatitis C therapy. <i>Future Virology</i> , 2006, 1, 99-107.	0.9	3
344	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011, 87, 223-238.	0.9	3
345	Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience. <i>Journal of Transplantation</i> , 2016, 2016, 1-22.	0.3	3
346	Transjugular diagnostics in acute liver failure including measurements of hepatocentral venous biomarker gradients. <i>Hepatology Research</i> , 2018, 48, 914-925.	1.8	3
347	Endoscopic biliary drainage in patients with cholangiocarcinoma – self-expanding metal versus polyethylene stents. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 640-645.	0.6	3
348	Utility of viral kinetics in HCV therapy – It is not over until it is over?. <i>Liver International</i> , 2019, 39, 815-817.	1.9	3
349	Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 99-108.	0.8	3
350	CK18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. <i>Liver International</i> , 2021, 41, 123-127.	1.9	3
351	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0134839.	1.1	3
352	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 223-229.	0.8	3
353	Adjuvant Therapy with Budesonide Post-Kasai Reduces the Need for Liver Transplantation in Biliary Atresia. <i>Journal of Clinical Medicine</i> , 2021, 10, 5758.	1.0	3
354	Reply:. <i>Hepatology</i> , 2006, 44, 511-512.	3.6	2
355	Telaprevir and Boceprevir: The Future Is Now. <i>Current Hepatitis Reports</i> , 2012, 11, 160-171.	0.3	2
356	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , 2015, 10, e0145622.	1.1	2
357	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. <i>PLoS ONE</i> , 2016, 11, e0168544.	1.1	2
358	Hepatitis D virus in Africa: several unmet needs. <i>The Lancet Global Health</i> , 2017, 5, e953-e954.	2.9	2
359	Effects of adenovirus-induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model. <i>Liver International</i> , 2019, 39, 2330-2340.	1.9	2
360	Endoscopic decompression of acute intestinal distension is associated with reduced mortality in critically ill patients. <i>BMC Gastroenterology</i> , 2020, 20, 87.	0.8	2

#	ARTICLE	IF	CITATIONS
361	Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. <i>Liver International</i> , 2020, 40, 1645-1654.	1.9	2
362	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. <i>Hepatology Communications</i> , 2022, 6, 621-632.	2.0	2
363	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. <i>Current Hepatitis Reports</i> , 2003, 2, 24-31.	0.3	1
364	Application of the Liver Maximum Function Capacity Test in Acute Liver Failure: A Helpful Tool for Decision-Making in Liver Transplantation?. <i>Case Reports in Transplantation</i> , 2016, 2016, 1-5.	0.1	1
365	Patients with primary sclerosing cholangitis require more sedation during endoscopic retrograde cholangiography. <i>Endoscopy International Open</i> , 2017, 05, E315-E320.	0.9	1
366	Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma – a case-control study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1398-1406.	0.6	1
367	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw572.	1.3	1
368	Editorial: “œreal world data” of AIH – time to connect!. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1315-1316.	1.9	1
369	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. <i>PLoS ONE</i> , 2019, 14, e0224751.	1.1	1
370	Surgical Procedures in Patients Awaiting Liver Transplantation: Complications and Impact on the Liver Function. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 68-79.	0.4	1
371	Primary sclerosing cholangitis with moderately elevated serum IgG4 – characterization and outcome of a distinct variant phenotype. <i>Liver International</i> , 2021, , .	1.9	1
372	The Role of Stem Cells in Physiology, Pathophysiology, and Therapy of the Liver. <i>Stem Cell Reviews and Reports</i> , 2006, 2, 51-58.	5.6	1
373	Anti-nuclear and anti-histone autoantibodies in autoimmune disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 453-456.	1.4	0
374	Treatment of chronic HCV infection in compensated and decompensated cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S94-S98.	1.4	0
375	New Diagnostic Technology in Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 307-308.	1.8	0
376	Prof. Daniel Shouval. <i>Journal of Hepatology</i> , 2009, 51, 620-622.	1.8	0
377	Update on the Management of HBV-HDV Coinfection. <i>Current Hepatitis Reports</i> , 2012, 11, 95-101.	0.3	0
378	Cholangiocarcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 219.	1.0	0

#	ARTICLE	IF	CITATIONS
379	An Unusual Cause of Chronic Diarrhea Treated by Interventional Radiology. <i>Gastroenterology</i> , 2015, 149, 1339-1340.	0.6	0
380	Silymarin for Treatment of Nonalcoholic Steatohepatitis—A New Kid on the Block?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1863-1865.	2.4	0
381	IDDF2018-ABS-0113—The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
382	Dilatation Therapy and Demographic Characteristics Significantly Influence the Amount of Propofol for Therapeutic Endoscopic Retrograde Cholangiography. <i>International Journal of Hepatology</i> , 2019, 2019, 1-6.	0.4	0
383	P174—Exploration of urinary peptides in hepatocellular carcinoma. , 2021, , .		0
384	Na ⁺ /H ⁺ exchanger isoform NHE3 and NHERF adaptor protein expression, localization and function in the small and large intestine of CD45RB high transfer colitis. <i>FASEB Journal</i> , 2009, 23, 570.9.	0.2	0
385	Dual role of the Na ⁺ /H ⁺ exchanger isoform 3 for PEPT1-mediated H ⁺ /dipeptide cotransport in native murine intestine. <i>FASEB Journal</i> , 2009, 23, 796.42.	0.2	0
386	Treatment strategies in patients with hepatocellular carcinoma in a real-life cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15630-e15630.	0.8	0
387	Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: A single-centre experience after 54 treatments.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15625-e15625.	0.8	0
388	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis. <i>Scientific Reports</i> , 2022, 12, 3285.	1.6	0